Figure 2 | Leukemia

Figure 2

From: RAS pathway mutations as a predictive biomarker for treatment adaptation in pediatric B-cell precursor acute lymphoblastic leukemia

Figure 2

Clinical outcome of patients carrying clonal or subclonal RAS pathway mutations. Event-free survival (left panel) and cumulative incidence of relapse and non-response (CIR, right panel) (a) within the ALL10 cohort (n=244) and (b) divided by the three risk arms of ALL10. Abbreviations: HR, high-risk group; MR, medium-risk group; Ptrend represents the P-value in a log-rank (EFS) or Gray-test (CIR) across all three groups, Pcl represents the P-value in a log-rank or Gray-test comparing wild-type patients and those with a clonal RAS pathway mutation; SR, standard-risk group.

Back to article page